Eton Pharmaceuticals Adds Another 2026 Launch As It Secures U.S. Rights To IMPAVIDO

Eton Pharmaceuticals secured exclusive U.S. commercialization rights to IMPAVIDO, the only FDA-approved oral therapy for multiple forms of leishmaniasis, adding another planned 2026 launch to its rare-disease portfolio. The deal expands the company’s future product pipeline and supports its growth strategy, though the near-term market impact is likely limited. The announcement is positive for long-term positioning but does not include financial terms or revenue guidance.

Analysis

Eton Pharmaceuticals secured exclusive U.S. commercialization rights to IMPAVIDO, the only FDA-approved oral therapy for multiple forms of leishmaniasis, adding another planned 2026 launch to its rare-disease portfolio. The deal expands the company’s future product pipeline and supports its growth strategy, though the near-term market impact is likely limited. The announcement is positive for long-term positioning but does not include financial terms or revenue guidance.